Literature DB >> 18162289

Kinetin riboside preferentially induces apoptosis by modulating Bcl-2 family proteins and caspase-3 in cancer cells.

Bo-Hwa Choi1, Wanil Kim, Qiuxia Chelsia Wang, Dong-Chan Kim, Swee Ngin Tan, Jean Wan Hong Yong, Kyong-Tai Kim, Ho Sup Yoon.   

Abstract

Here, we demonstrate that kinetin riboside (KR), a cytokinin analog, induces apoptosis in HeLa and mouse melanoma B16F-10 cells. KR disrupted the mitochondrial membrane potential and induced the release of cytochrome c and activation of caspase-3. Bad were upregulated while Bcl-2 was down-regulated under KR exposure. A tumor growth in mice was dramatically suppressed by KR. In contrast, human skin fibroblast CCL-116 and bovine primary fibroblast cells show resistances to KR and no significant changes in Bad, Bcl-X(L,) and cleaved PARP were observed. Our data suggest that KR selectively induces apoptosis in cancer cells through the classical mitochondria dependent apoptosis pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18162289     DOI: 10.1016/j.canlet.2007.11.014

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

1.  Japonicone A inhibits the growth of non-small cell lung cancer cells via mitochondria-mediated pathways.

Authors:  Yan Du; Jiannan Gong; Xinrui Tian; Xiaomei Yan; Tao Guo; Min Huang; Bingtai Zhang; Xiaoyun Hu; Hui Liu; Yinping Wang; Jianqiang Li; Maolan Li
Journal:  Tumour Biol       Date:  2015-04-25

2.  Overexpression of Bcl-2-associated death inhibits A549 cell growth in vitro and in vivo.

Authors:  Na Huang; Jing Zhu; Dan Liu; Ya-Lun Li; Bo-Jiang Chen; Yan-Qi He; Kun Liu; Xian-Ming Mo; Wei-Min Li
Journal:  Cancer Biother Radiopharm       Date:  2011-10-19       Impact factor: 3.099

3.  Oxymatrine triggers apoptosis by regulating Bcl-2 family proteins and activating caspase-3/caspase-9 pathway in human leukemia HL-60 cells.

Authors:  Jun Liu; Yazhou Yao; Huifang Ding; Renan Chen
Journal:  Tumour Biol       Date:  2014-02-23

4.  Could the kinetin riboside be used to inhibit human prostate cell epithelial-mesenchymal transition?

Authors:  Joanna Dulińska-Litewka; Bartosz Gąsiorkiewicz; Aleksandra Litewka; Dorota Gil; Tomasz Gołąbek; Krzysztof Okoń
Journal:  Med Oncol       Date:  2020-02-06       Impact factor: 3.064

5.  FKBP38 protects Bcl-2 from caspase-dependent degradation.

Authors:  Bo-Hwa Choi; Lin Feng; Ho Sup Yoon
Journal:  J Biol Chem       Date:  2010-02-05       Impact factor: 5.157

6.  The experimental chemotherapeutic N6-furfuryladenosine (kinetin-riboside) induces rapid ATP depletion, genotoxic stress, and CDKN1A(p21) upregulation in human cancer cell lines.

Authors:  Christopher M Cabello; Warner B Bair; Stephanie Ley; Sarah D Lamore; Sara Azimian; Georg T Wondrak
Journal:  Biochem Pharmacol       Date:  2008-12-24       Impact factor: 5.858

7.  Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.

Authors:  Ming-Rong Cheng; Qing Li; Tao Wan; Bing He; Jiang Han; Hou-Xiang Chen; Feng-Xiao Yang; Wei Wang; Hong-Zhi Xu; Tao Ye; Bing-Bing Zha
Journal:  World J Gastroenterol       Date:  2012-11-14       Impact factor: 5.742

8.  In vitro cytotoxicity and induction of apoptosis by silica nanoparticles in human HepG2 hepatoma cells.

Authors:  Xun Lu; Jiangchao Qian; Huanjun Zhou; Qi Gan; Wei Tang; Jingxiong Lu; Yuan Yuan; Changsheng Liu
Journal:  Int J Nanomedicine       Date:  2011-09-07

9.  Implications of Oxidative Stress in Glioblastoma Multiforme Following Treatment with Purine Derivatives.

Authors:  Marta Orlicka-Płocka; Agnieszka Fedoruk-Wyszomirska; Dorota Gurda-Woźna; Paweł Pawelczak; Patrycja Krawczyk; Małgorzata Giel-Pietraszuk; Grzegorz Framski; Tomasz Ostrowski; Eliza Wyszko
Journal:  Antioxidants (Basel)       Date:  2021-06-12

10.  5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model.

Authors:  Mingrong Cheng; Bing He; Tao Wan; Weiping Zhu; Jiang Han; Bingbing Zha; Houxiang Chen; Fengxiao Yang; Qing Li; Wei Wang; Hongzhi Xu; Tao Ye
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.